-
Bullying claims 'nonsense', actress Rebel Wilson tells Sydney court
-
BP reports huge profit rise in first quarter
-
Crude extends gains, stocks drop as Trump considers latest Iran proposal
-
How China block of AI deal could stop 'Singapore-washing'
-
North Korean executions rose dramatically during Covid: report
-
Budget airlines first to cut flights as jet fuel prices soar
-
Simeone, Atletico chasing redemption against Arsenal
-
'Bring it on', says Rice as Arsenal chase Champions League history
-
US says examining latest Iran proposal
-
S. Korea probes syringe hoarding as war hits plastic makers
-
Australia aims to tax tech giants unless they pay news outlets
-
Bangladesh's tigers stalk uncertain future in Sundarbans
-
Horses unlikely saviours for those who serve in uniform
-
Crude extends gains as Trump considers latest Iran proposal
-
Nations to kick off world-first fossil fuel exit talks
-
Philippine museum brings deadly, lucrative galleon trade to life
-
Opening remarks Tuesday in Elon Musk versus OpenAI
-
New York restaurant's $40 half chicken fuels cost of dining debate
-
Trump shooting scare renews 'staged' conspiracy theory
-
LIV Golf postpones June event set for New Orleans: reports
-
Kingfisher Metals Confirms Early Jurassic Porphyry Mineralization Across Hank-Mary District, a Fertile Window Between Mitchell Cu-Au and Brucejack Au-Ag Deposits
-
Star Copper Completes Copperline Project Inaugural 2025 Field Program at Omineca Mining Division, BC
-
BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum
-
SphingoTec Introduces ELISA sphingotest(R) penKid(R) to Enable Broad Kidney Biomarker Testing for Research Applications
-
Apex Drills 4.02% REO over 23.7 m, within Broader 124 m Zone at 1.94% REO, Extending Mineralization Significantly to the South
-
Hemogenyx Pharmaceuticals PLC Announces Institutional Fundraise
-
Caledonia Mining Corporation Plc: Notice of Q1 2026 Results and Investor Presentation
-
Genflow Biosciences PLC Announces Expansion of Confidentiality Agreements
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - April 28
-
Colombian peace accord failed to protect nature: ex-leader Santos
-
Nations have chance to break 'fossil fuel mindset': Mary Robinson
-
Colombia in mourning after deadliest attack in decades
-
Jury in place for Elon Musk's legal battle with OpenAI
-
Weinstein rape accuser gives emotional testimony at US retrial
-
Rybakina crashes out of Madrid Open, Sabalenka reaches quarters
-
Trump and team renew attacks on adversaries after gala shooting
-
Carrick hails Casemiro and Fernandes after vital Man Utd win
-
Felix, 40, says she plans comeback for LA Olympics
-
French FM says Iran must make 'major concessions' to end crisis
-
Trains collide near Jakarta, killing five, injuring dozens
-
Britain's King Charles meets Trump in bid to salvage ties
-
Accused media gala gunman charged with attempting to assassinate Trump
-
Man Utd beat Brentford to close on Champions League berth
-
Third suspect pleads guilty in US murder of Jam Master Jay
-
Milei bars media from presidential palace
-
California billionaire tax appears headed to the ballot
-
Trains collide near Jakarta, killing four, injuring dozens
-
Kompany hails Kane, 'ageing like fine wine' as Bayern face PSG in Champions League
-
UK's King Charles arrives in US to shore up Trump ties
-
Tuareg rebels in control of key Mali town
PetVivo Holdings, Inc. Announces Participation in The Microcap Conference 2025
PetVivo Holdings, Inc. (OTCQB:PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals, is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.
John Lai, Chief Executive Officer of PetVivo Holdings, Inc. will provide a Company overview as well as discuss its lead product, SPRYNG™ with OsteoCushion™ Technology. Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal's subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
About The Microcap Conference 2025
The Microcap Conference is the largest independent microcap event in the U.S., bringing together top-tier investors and executives from microcap companies. The event offers a platform for companies to showcase their value propositions through presentations, one-on-one meetings, and networking opportunities.
The 2025 event will feature:
Keynote Speakers: Renowned industry figures, including Jon Ledecky, Co-Owner of the New York Islanders, who will engage in a fireside chat with CNBC's Bob Pisani; plus Tom Gardner, CEO of Motley Fool, who will share insights on investing, market trends, and entrepreneurial success.
Expert Panels and Presentations: Financial commentators Ron Insana (CNBC) and Charlie Gasparino (FOX Business) will cover critical topics for the US equity markets, from capital formation to regulatory updates and market trends.
Entertainment Headliner: A special performance by Tom Papa, celebrated comedian and host of Netflix specials, ensuring a memorable evening for attendees.
Hosted by DealFlow Events, The Microcap Conference is renowned for its blend of high-quality content, engaging networking, and exceptional entertainment. For more information, visit https://themicrocapconference.com.
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB:PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company's commercially launched flagship product, Spryng™ with OsteoCushion™ Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.
For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email [email protected] or visit petvivo.com or sprynghealth.com.
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company's Investor Relations website, in addition to following the company's press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the "Company") may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
SOURCE: PetVivo Holdings, Inc.
P.Stevenson--AMWN